乌龙丹联合柳氮磺吡啶治疗强直性脊柱炎36例  

Wulongdan Combined with Sulfasalazine in the Treatment of Ankylosing Spondylitis:Analysis of 36 Cases

作　　者：慈玉莹[1] 陈文阁[1] 李泽光[1] 黄吉峰[1] 

机构地区：[1]黑龙江中医药大学附属第一医院,黑龙江哈尔滨150040

出　　处：《中医药学报》2014年第3期151-153,共3页Acta Chinese Medicine and Pharmacology

摘　　要：目的:观察乌龙丹联合柳氮磺吡啶治疗强直性脊柱炎的疗效与安全性。方法:66例门诊患者随机分为治疗组36例和对照组30例,治疗组给予乌龙丹联合柳氮磺吡啶治疗,对照组给予柳氮磺吡啶治疗,两组均在必要时给予NSAIDs治疗并记录剂量及用药天数。观察治疗前后两组患者临床疗效及实验室指标改变情况。结果:治疗12周后,两组患者在晨僵时间、ESR、CRP、BASFI、BASDAI均比治疗前有显著改善(P<0.05),且治疗组优于对照组(P<0.05)。治疗组有效率高于对照组(P<0.05),且不良反应较对照组少(P<0.05)。结论:乌龙丹联合柳氮磺吡啶治疗强直性脊柱炎有良好疗效。Objective：To observe the efficacy and safety of Wulongdan combined with sulfasalazine on ankylosing spondy -litis.Methods：66 cases of outpatients were randomly divided into a treatment group with 36 patients and a control group with 30 patients.The treatment group received Wulongdan combined with sulfasalazine therapy ,and the control group was given sulfasalazine treatment .Both groups were given NSAIDs therapy when necessary and record the dose and the num-ber of days of medication .Before and after treatment observe two groups of patients according to efficacy and laboratory parameters to change the situation .Results： After 12 weeks of treatment , patients in both groups according to time of morning stiffness, ESR, CRP, BASFI, BASDAI were more significantly than before treatment （P〈0.05）, and the treatment group was superior to the control group （P〈0.05）.The clinical effectiveness of the treatment group was high-er （P〈0.05）, and fewer side effects than that in the control group （P〈0.05）.Conclusion： Wulongdan combined with sulfasalazine in the treatment of ankylosing spondylitis has a good effect .

关 键 词：强直性脊柱炎 乌龙丹 柳氮磺吡啶 

分 类 号：R593.23[医药卫生—内科学]